The Berlin-Dresden NAFLD Joint Research Initiative seeks to address the pressing need to find effective treatment options for non-alcoholic fatty liver disease (NAFLD). Several recently failed clinical trials have set back the NAFLD field and have made it evident that the concept of “one fits all” therapy may not be suitable for the multiple and heterogeneous disease-driving mechanisms in patients suffering from NAFLD. Hence, an entirely fresh look to NAFLD pathogenesis and therapeutic approach is required, which has motivated us to form a new center, composed of basic and clinical investigators with expertise in metabolism, immunology, fibrosis and systems biology. Our initiative includes investigators from Charité – Universitätsmedizin Berlin and Technische Universität Dresden as well as from the Berlin Institute of Health (BIH, Berlin), the Max-Delbrück-Centrum (MDC, Berlin), and the Max Planck Institute of Molecular Cell Biology and Genetics (MPI-CBP, Dresden).
© 2022 | Berlin Dresden NAFLD Joint Research Initiative | All Rights Reserved